Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
409 stopped studies mapped to Mature B-Cell Non-Hodgkin Lymphoma and descendants · 88% state a reason
Over the 409 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05265975 | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With…(SWATCH) | Phase 1 / Phase 2 | terminated | Mar 4, 2022 | Antengene Corporation | The adjustment of the sponsor's research and development strategy | Sponsor / business decision |
| NCT06839872 | A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression…(BOSS) | Phase 2 | withdrawn | Feb 21, 2025 | AstraZeneca | AstraZeneca has made the decision to cancel the trial. | Other (stated, no rule matched) |
| NCT04034446 | CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute… | Early Phase 1 | terminated | Jul 26, 2019 | Institute of Hematology & Blood Diseases Hospital, China | Due to adjustments in the company's strategy, the research and development of this project has been… | Sponsor / business decision |
| NCT04189952 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | Phase 2 | terminated | Dec 6, 2019 | University of Miami | Investigator Decision | Investigator |
| NCT03432741 | Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With… | Phase 1 | terminated | Feb 14, 2018 | Mayo Clinic | funding - sponsor filing Chapter 11 bankruptcy | Funding |
| NCT05788289 | A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma | Phase 2 | terminated | Mar 28, 2023 | Memorial Sloan Kettering Cancer Center | Slow accrual rate | Enrollment / accrual |
| NCT04694560 | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and… | — | withdrawn | Jan 5, 2021 | Memorial Sloan Kettering Cancer Center | Lack of potential participants given the other treatment options currently available to people | Other (stated, no rule matched) |
| NCT02966730 | Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial… | Early Phase 1 | terminated | Nov 17, 2016 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT02823327 | Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma | — | terminated | Jul 6, 2016 | AIDS Malignancy Consortium | Poor accrual | Enrollment / accrual |
| NCT06290622 | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | Phase 1 | withdrawn | Mar 4, 2024 | University of Alabama at Birmingham | Investigator request to no longer pursue this study. Lack of support from drug company. This trial… | Investigator |
| NCT04668365 | Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With… | Phase 2 | suspended | Dec 16, 2020 | Henan Cancer Hospital | Data in analysis | Other (stated, no rule matched) |
| NCT04047797 | Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell… | Phase 2 | terminated | Aug 7, 2019 | M.D. Anderson Cancer Center | Administratively Complete 75%\<Participants | Other (stated, no rule matched) |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | Phase 1 / Phase 2 | terminated | Apr 10, 2018 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. A new study in CLL patients is planned. | Other (stated, no rule matched) |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with… | Phase 1 | terminated | Sep 17, 2020 | IGM Biosciences, Inc. | Study terminated due strategic corporate pivot to focus on auto-immune indications | Sponsor / business decision |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With…(R/R) | Phase 1 / Phase 2 | terminated | Jun 5, 2020 | Aprea Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT04982471 | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | — | terminated | Jul 29, 2021 | Celgene | Slow accrual | Enrollment / accrual |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's… | Phase 1 | terminated | Mar 28, 2019 | Aptose Biosciences Inc. | Change in corporate strategy | Sponsor / business decision |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | Phase 2 | terminated | Feb 11, 2021 | Columbia University | Enrollment challenges | Enrollment / accrual |
| NCT04781855 | Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia… | Phase 1 | withdrawn | Mar 4, 2021 | M.D. Anderson Cancer Center | 0% Participants | Other (stated, no rule matched) |
| NCT04052061 | QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma | Phase 1 | withdrawn | Aug 9, 2019 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04517435 | ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | terminated | Aug 18, 2020 | Deepa Jagadeesh | Funding unavailable | Funding |
| NCT03636503 | Rituximab + Immunotherapy in Follicular Lymphoma | Phase 1 | terminated | Aug 17, 2018 | Dana-Farber Cancer Institute | Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients… | Drug supply |
| NCT02413489 | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory… | Phase 2 | terminated | Apr 10, 2015 | Janssen Research & Development, LLC | DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL cohort… | Efficacy / futility |
| NCT02743546 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab… | Phase 1 | withdrawn | Apr 19, 2016 | Janssen Research & Development, LLC | not stated | Not stated |
| NCT05144009 | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated…(LOTIS-9) | Phase 2 | terminated | Dec 3, 2021 | ADC Therapeutics S.A. | The benefit-risk profile does not support continuation of the LOTIS-9 trial. | Other (stated, no rule matched) |
| NCT04305444 | Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R… | Phase 2 | terminated | Mar 12, 2020 | Zhejiang DTRM Biopharma | Despite the efforts of our dedicated team and initial progress, we were unable to secure the… | Funding |
| NCT03768505 | Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After… | Phase 2 | terminated | Dec 7, 2018 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT03890289 | Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma(GAUDEALIS) | Phase 2 | terminated | Mar 26, 2019 | Fondazione Italiana Linfomi - ETS | Study was halted prematurely due to safety, since tocity stopping rules have been met | Safety / toxicity |
| NCT04745832 | Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL… | Phase 3 | terminated | Feb 9, 2021 | MEI Pharma, Inc. | Discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT03311126 | Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle… | Phase 2 | terminated | Oct 16, 2017 | University of Wisconsin, Madison | slow accrual | Enrollment / accrual |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell… | Phase 1 / Phase 2 | terminated | Apr 24, 2020 | Genmab | Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on… | Safety / toxicity |
| NCT05521178 | Cardiotoxicities in Patients Receiving BTKi | — | withdrawn | Aug 30, 2022 | Dana-Farber Cancer Institute | Funding for study was withdrawn | Funding |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT02298816 | B-Cell Hematologic Malignancy Vaccination Registry(HMvax-Regist) | — | withdrawn | Nov 24, 2014 | Wake Forest University Health Sciences | No patients enrolled | Enrollment / accrual |
| NCT03136497 | A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory… | Phase 1 | terminated | May 2, 2017 | Hackensack Meridian Health | Lack of enrollment | Enrollment / accrual |
| NCT04659044 | Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment… | Phase 2 | terminated | Dec 9, 2020 | Academic and Community Cancer Research United | Trial closed due to low accrual rate | Enrollment / accrual |
| NCT03530683 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801),… | Phase 1 | terminated | May 21, 2018 | Pfizer | A business decision was made by Pfizer to terminate the study. Termination was not due to any… | Safety / toxicity |
| NCT04852822 | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic… | — | terminated | Apr 21, 2021 | University of Washington | The study ended earlier than anticipated due to slow accrual. | Enrollment / accrual |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell… | Phase 1 | terminated | Mar 19, 2021 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT04082936 | A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | Sep 10, 2019 | IGM Biosciences, Inc. | Strategic Pipeline Prioritization: Clinical development of imvotamab in autoimmune diseases… | Sponsor / business decision |
| NCT05360238 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or… | Phase 1 / Phase 2 | terminated | May 4, 2022 | Mustang Bio | Business reasons | Sponsor / business decision |
| NCT05645744 | Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell… | — | terminated | Dec 9, 2022 | Mustang Bio | Business Reasons | Sponsor / business decision |
| NCT05272813 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | Phase 1 / Phase 2 | terminated | Mar 9, 2022 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | Phase 1 / Phase 2 | terminated | Feb 9, 2023 | MingSight Pharmaceuticals, Inc | The study is terminated due to major protocol revisions. | Other (stated, no rule matched) |
| NCT05936229 | Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy | Phase 1 / Phase 2 | withdrawn | Jul 7, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual, no participants enrolled | Enrollment / accrual |
| NCT04933617 | Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and… | Phase 1 | terminated | Jun 22, 2021 | National Cancer Institute (NCI) | The study was terminated early because copanlisib was removed from the market by the Food and Drug… | Drug supply |
| NCT02295722 | GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma(GEMHDM2014) | Phase 1 / Phase 2 | terminated | Nov 20, 2014 | AHS Cancer Control Alberta | It did not show a significant benefit to justify completing the full target accrual. | Enrollment / accrual |
| NCT05048732 | Imaging Apoptosis for Lymphoma Treatment Response | Early Phase 1 | terminated | Sep 17, 2021 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT04722601 | A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular… | Phase 1 / Phase 2 | terminated | Jan 25, 2021 | University of Chicago | funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 9, 2025source: clinicaltrials